Will Centene achieve adjusted diluted EPS of at least $3.00 for FY2026?
Current Prediction
Prediction Distribution
Individual Predictions(9 runs)
FY2025 delivered $2.08. $3.00 requires 44% improvement. Key drivers: ACA contraction improving HBR, Medicaid rate increases. Management withdrew guidance in 2025 — credibility impaired. Guide beat consensus of $2.50.
Multiple assumptions must hold simultaneously: HBR improvement, ACA contraction, no incremental risk adj losses. Joint probability lower. Management track record poor.
MCOs historically deliver after reset years. The $3.00 may be sandbagged with upside. ACA contraction is the key catalyst.
Pre-guidance consensus $2.50 reflects analyst skepticism. Credibility discount warranted after July 2025 withdrawal.
True coin-flip. Arguments balanced. ACA contraction helps but adverse selection could offset.
All segments must improve simultaneously with 3 different headwinds. Joint probability below 50%.
44% growth needed from impaired management. Near coin-flip.
Clear improvement drivers exist but execution risk high.
Base case slightly below $3.00. Multiple headwinds could offset drivers.
Resolution Criteria
Resolves YES if Centene's FY2026 full-year adjusted diluted EPS (as reported in the FY2026 earnings release, expected February 2027) is $3.00 or above. Resolves NO if below $3.00. Uses Centene's definition of adjusted diluted EPS as reported.
Resolution Source
Centene FY2026 earnings release
Source Trigger
FY2026 adjusted diluted EPS guidance of at least $3.00 — credibility test after FY2025 miss
Full multi-lens equity analysis